Stem Pharm, Inc

Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include medical devices for drug discovery, cell therapy, and regenerative medicine. Stem Pharm's synthetic biomaterials support the optimization of cell expansion and differentiation, human tissue formation and cell/tissue delivery applications. Through control of the biomaterial properties (e.g. mechanical stiffness, cell adhesion, degradability), and utilizing chemistries that maintain cellular health and function, we provide cell-specific biomaterials to researchers and clinicians to fill unmet needs in their workflows. Currently, cell and tissue manufacturing processes often rely on animal-derived biomaterials that are complex and variable in nature and problematic for human in vivo applications due to potential pathogen transmission or an immunogenic response. Our materials are synthetic, defined, and optimized to produce functional cells and tissues and deliver them to areas of clinical need.

Related News

MEDICAL

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

news image

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

news image

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

news image

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More

MEDICAL

THERMO FISHER SCIENTIFIC AND QATAR GENOME PROGRAM PARTNER TO ADVANCE PRECISION MEDICINE

Thermo Fisher Scientific | May 24, 2022

news image

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using w...

Read More
news image

MEDICAL

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More
news image

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More
news image

BIOMEME, INC. ANNOUNCES SARS-COV-2 TEST APPROVAL BY FDA UNDER THE EMERGENCY USE AUTHORIZATION

Biomeme | August 20, 2020

Biomeme, Inc. announced today that the U.S. Food and Drug Administration (FDA) gave Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use in any lab CLIA-certified to perform high complexity testing. It is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. The Biomeme SARS-CoV-2 Real-Time RT-PCR Test is designed to detect the virus&r...

Read More
news image

MEDICAL

THERMO FISHER SCIENTIFIC AND QATAR GENOME PROGRAM PARTNER TO ADVANCE PRECISION MEDICINE

Thermo Fisher Scientific | May 24, 2022

Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. Under the agreement, Thermo Fisher and Qatar Genome Program will develop an Axiom* custom genotyping array for pan-Arab populations using w...

Read More